Teriparatide: A bone formation treatment for osteoporosis.
Teriparatide is the recombinant human N-terminal fragment (1-34) of endogenous human parathyroid hormone, and it is the first bone anabolic agent for the treatment of osteoporosis. When given as once-daily subcutaneous injections, teriparatide can reverse the course of osteoporosis by stimulating formation of new bone and restoring lost architecture. Teriparatide (20 microg) treatment of osteoporosis in postmenopausal women rapidly increased markers of bone formation and reduced the incidence of vertebral fractures by 65% and of nonvertebral fragility fractures by 53%. In addition, treatment with this compound increased spine bone mineral density by 10% and hip bone mineral density by 3% at study endpoint. Teriparatide is well tolerated and is not associated with any serious side effects. The compound has been approved in Europe and in the US for the treatment of osteoporosis. Duration of treatment is 18-24 months and the dose does not need to be adjusted for age or gender.
Eriksen
Erik F
EF
Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285, USA. eriksen_erik_f@lilly.com
Robins
Deborah A
DA
D000368:Aged; D001682:Biological Availability; D015519:Bone Density / Q000187:drug effects; D005260:Female; D050723:Fractures, Bone / Q000209:etiology* / Q000517:prevention & control; D006207:Half-Life; D006801:Humans; D008297:Male; D010012:Osteogenesis / Q000187:drug effects*; D010024:Osteoporosis / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D015663:Osteoporosis, Postmenopausal / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D016032:Randomized Controlled Trials as Topic; D019379:Teriparatide / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use
D019379:Teriparatide